HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Exacerbation of porokeratosis during etretinate therapy.

Abstract
Four patients with disseminated superficial porokeratosis (DSP) were treated with the oral aromatic retinoid etretinate. Using the standard dosage of 1 mg/kg/day, 3 patients showed exacerbation of cutaneous lesions 4-6 weeks after initiation of treatment. Because of additional severe generalized itching and discomfort in all patients, treatment had to be discontinued. The clinical exacerbation correlated with a significant increase in the lymphohistiocytic dermal infiltrate beneath the cornoid lamella. In our experience the use of etretinate triggered the exacerbation of porokeratotic lesions with associated side effects showing that their use is not necessarily of benefit as previously reported.
AuthorsR M Knobler, R A Neumann
JournalActa dermato-venereologica (Acta Derm Venereol) Vol. 70 Issue 4 Pg. 319-22 ( 1990) ISSN: 0001-5555 [Print] Sweden
PMID1977257 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Etretinate
Topics
  • Aged
  • Biopsy
  • Etretinate (administration & dosage, adverse effects)
  • Female
  • Humans
  • Keratosis (chemically induced, drug therapy, genetics)
  • Male
  • Middle Aged
  • Skin (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: